Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen- independence after castration in the Shionogi tumor model

Cancer Research

Volumn 59, Issue 16, 1999, Pages 4030-4034

  Miyake, Hideaki ^a   Tolcher, Anthony ^b   Gleave, Martin E ^a,c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PROTEIN BCL 2;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CASTRATION; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR MODEL; TUMOR REGRESSION;

ANDROGENS; ANIMALS; FEMALE; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0033567003     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Denis, L., and Murphy, G. P. Overview of Phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (Phila. ), 72: 3888-3895, 1993.
2. Oh, W. K., and Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol., 160: 1220-1229, 1998.
3. Tsujimoto Y., and Croce, C. M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA, 83: 5214-5218, 1986.
4. Raffo, A. J., Periman, H., Chen, M. W., Streitman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
5. McConkey, D. J., Greene, G., and Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res., 56: 5594-5599, 1996.
6. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Moul, J. W. Elevated levels of apoptosis regulatory proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511-1516, 1996.
7. j-67 labeling index, p53 and Bcl-2 immunoreactivity. J. Urol., 159: 1437-1443, 1998.
8. McDonnell, T. J., Troncoso, P., Brisby, S. M., Logothesis, C. L., Chung, L. W. K., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
9. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Choplin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol., 143: 390-400, 1993.
10. Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M., and Lawson, D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 50: 2275-2282, 1990.
11. Crooke, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol., 32: 329-376, 1993.
12. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2: 668-675, 1996.
13. Cucco, C., and Calabretta, B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res., 56: 4332-4337, 1996.
14. Ziegler, A., Luedke, G. H., Fabbro, D., Altman, K. H., Stahel, R. A., and Zangemeister-Wittke, U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst., 89: 1027-1036, 1997.
15. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elisa, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
16. Rennie, P. S., Bruchovsky, N., Buttyan, R., and Cheng, H. Gene expression during the early phase of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res., 48: 6309-6312, 1988.
17. Bruchovsky, N., and Rennie, P. S. Classification of dependent and autonomous variants of Shionogi mammary carcinoma based on heterogeneous patterns of androgen binding. Cell, 13: 272-280, 1978.
18. Gleave, M. E., Hsieh, J. T., Wu, H-C., and Chung, L. W. K. Serum PSA levels in mice bearing human prostate LNCaP tumor are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598-1605, 1992.
19. Gleave, M. E., Hsieh, J. T., Gao, C., von Eschenbach, A. C., and Chung, L. W. K. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 3753-3761, 1991.
20. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (Lond. ), 371: 346-347, 1994.
21. Negrini, M., Silini, E., Kozak, C., Tsujimoto, Y., and Croce, C. M. Molecular analysis of mbcl-2: structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma. Cell, 49: 455-463, 1987.
22. Saijo, Y., Perlaky, L., Wang, H., and Busch, H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res., 6: 243-249, 1994.
23. Dorai, T., Olsson, C. A., Katz, A. E., and Buttyan, R. Development of a hammerhead riboenzyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate, 32: 246-258, 1997.
24. Stein, C. A., and Cheng, Y. C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (Washington DC), 261: 1004-1012, 1993.
25. Stein, C. A. Does antisense exist? Nat. Med., 1: 1119-1121, 1995.
26. Wooldridge, J. E., Ballas, Z., Krieg, A. M., and Weiner, G. J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal therapy of lymphoma. Blood, 89: 2994-2998, 1997.
27. Crooke, S. T., Lemonidis, K. M., Neilson, L., Griffey, R., Lesnik, E. A., and Monia, B. P. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J., 312: 599-608, 1995.
28. Gao, W. Y., Han, F. S., Storm, C., Egan, W., and Cheng, Y. C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol., 41: 223-229, 1992.
29. Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkison, J. L., and Stein, C. A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem., 270: 2620-2627, 1995.
30. Hoehn, W., Schroeder, F. H., Riemann, J. F., Joebsis, A. C., and Hermanek, P. Human prostatic adenocarcinoma: Some characteristics of a serially transplantable line in nude mice (PC82). Prostate, 1: 95-104, 1980.
31. Chen D. F., Sehneider, G. E., Martinou, J. C., and Tonegawa, S. Bcl-2 promotes regeneration of served axons in mammalian CNS. Nature (Lond. ), 385: 443-449, 1997.
32. Williams, O., Norton, T., Halligey, M., Kioussis, D., and Brady, H. J. M. The action of Bax and bcl-2 on T cell selection. J. Exp. Med., 188: 1125-1133, 1998.
33. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.